PMID- 12551823
OWN - NLM
STAT- MEDLINE
DCOM- 20030611
LR  - 20171116
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 88
IP  - 1
DP  - 2003 Jan
TI  - Interphase fluorescence in situ hybridization assay for the detection of 
      rearrangements of the EVI-1 locus in chromosome band 3q26 in myeloid 
      malignancies.
PG  - 25-30
AB  - BACKGROUND AND OBJECTIVES: Rearrangements of the EVI-1 locus in chromosome band 
      3q26 are associated with a poor prognosis in myeloid malignancies. To aid the 
      diagnosis of such aberrations, and possibly disease monitoring, we established an 
      interphase fluorescence in situ hybridization (FISH) assay for the affected 
      breakpoint region. DESIGN AND METHODS: Several overlapping PAC (P1-derived 
      artificial chromosome) clones centromeric to the EVI-1 gene were labeled with a 
      red fluorescent dye, and PAC clones telomeric to EVI-1 with a green fluorochrome. 
      This dual-color probe was hybridized to cytogenetic preparations of cell lines 
      and patients' samples, which were also investigated for the presence of 3q26 
      rearrangements by chromosome banding analysis. RESULTS: In nuclei without 3q26 
      rearrangements, two pairs of co-localized red and green signals were observed, 
      while separation of one red/green signal pair or splitting of one red or one 
      green signal was found when 3q26 aberrations were present. The threshold value 
      for true positivity, as determined on 20 samples from patients with myeloid 
      malignancies without 3q26 rearrangements, was 10.2% for separation of one 
      red/green signal pair, and 1% and 1.3% for splitting of one red or one green 
      signal, respectively. In 17 samples from patients with a 3q26 aberration, the 
      percentage of aberrant cells was significantly above these threshold levels. 
      INTERPRETATION AND CONCLUSIONS: We established an interphase FISH assay that 
      efficiently identifies chromosome breakpoints affecting the EVI-1 locus in 3q26, 
      and represents a useful complement to chromosome banding analysis for the 
      detection of such aberrations.
FAU - Wieser, Rotraud
AU  - Wieser R
AD  - Institut fur Medizinische Biologie der Universitaet Wien, Austria. 
      rotraud.wieser@univie.ac.at
FAU - Schreiner, Ulrike
AU  - Schreiner U
FAU - Rieder, Harald
AU  - Rieder H
FAU - Pirc-Danoewinata, Hendrati
AU  - Pirc-Danoewinata H
FAU - Gruner, Helga
AU  - Gruner H
FAU - Loncarevic, Ivan F
AU  - Loncarevic IF
FAU - Fonatsch, Christa
AU  - Fonatsch C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MDS1 and EVI1 Complex Locus Protein)
RN  - 0 (MECOM protein, human)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - *Chromosomes, Human, Pair 3
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/pathology
MH  - Leukemia, Myeloid/*genetics/pathology
MH  - MDS1 and EVI1 Complex Locus Protein
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*genetics/pathology
MH  - *Proto-Oncogenes
MH  - *Transcription Factors
EDAT- 2003/01/29 04:00
MHDA- 2003/06/12 05:00
CRDT- 2003/01/29 04:00
PHST- 2003/01/29 04:00 [pubmed]
PHST- 2003/06/12 05:00 [medline]
PHST- 2003/01/29 04:00 [entrez]
PST - ppublish
SO  - Haematologica. 2003 Jan;88(1):25-30.